Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients
Zhi-wei Chen,* Xi-chen Pang,* Zhao Li, Hong Ren, Peng Hu Department of Infectious Diseases, Institute for Viral Hepatitis, The Key Laboratory of Molecular Biology for Infectious Diseases, Chinese Ministry of Education, The Second Affiliated Hospital of Chongqing M...
Main Authors: | Chen Z, Pang X, Li Z, Ren H, Hu P |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-08-01
|
Series: | Infection and Drug Resistance |
Subjects: | |
Online Access: | https://www.dovepress.com/pegylated-interferon-plus-ribavirin-treatment-does-not-alter-the-preva-peer-reviewed-article-IDR |
Similar Items
-
Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin
by: Janine Hartl, et al.
Published: (2012-07-01) -
Pegylated Interferon (Alone or With Ribavirin) for Chronic Hepatitis C in Haemodialysis Population
by: Mario Espinosa, et al.
Published: (2015-05-01) -
Combined pegylated interferon and ribavirin for the management of chronic hepatitis C in a prison setting
by: Sergio Sabbatani, et al. -
Efficacy of combined antiviral therapy with pegylated interferon α-2a and ribavirin for chronic hepatitis C infection in intravenous drug users
by: Ružić Maja, et al.
Published: (2010-01-01) -
Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection
by: Sundaram V, et al.
Published: (2016-06-01)